Two Companies Pay $67 Million for Tarceva FCA Claims

Genentech Inc. and OSI Pharmaceuticals LLC have agreed to pay $67 million to resolve allegations that they overstated the effectiveness of cancer drug Tarceva for certain conditions.  According to the DOJ press release:

The settlement resolves allegations that, between January 2006 and December 2011,  Genentech and OSI Pharmaceuticals made misleading representations to physicians and other health care providers about the effectiveness of Tarceva to treat certain patients with non-small cell lung cancer, when there was little evidence to show that Tarceva was effective to treat those patients unless they also had never smoked or had a mutation in their epidermal growth factor receptor, which is a protein involved in the growth and spread of cancer cells.

The whistleblower who brought the allegations to the government’s attention will receive $10 million as a reward for bringing the case.

Read the DOJ press release